Critique: FDA cliffhanger: Makary's fate in limbo

Source: axios
Authors: Adriel Bettelheim
URL: https://www.axios.com/2026/05/11/fda-cliffhanger-makary-trump-administration

What the article reports

Reports circulated on Friday, May 9, 2026, that FDA Commissioner Marty Makary was about to be fired; Trump publicly denied knowledge of the reports, and a White House official attributed the push to HHS leadership. The piece surveys Makary's brief tenure, names possible successors, and quotes two Wall Street analysts on what the FDA leadership situation means for industry and drug-review staffing.

Factual accuracy — Adequate

Most verifiable claims are plausible and narrowly stated. The characterization that "the FDA regulates about one-fifth of the U.S. economy" is a widely cited figure that checks out. Makary's affiliation with Johns Hopkins as a "physician and researcher" is accurate. The specific staffing claim — "biologics and drug evaluation centers each down more than 19% since Trump took office" — is attributed to Raymond James analyst Chris Meekins and sourced to hiring data, though the underlying data are not linked or described, making independent verification difficult. The characterization of Moderna's mRNA flu shot as one "the agency initially refused to evaluate, before reversing itself" is specific and reported elsewhere, but no timeline or source is offered. Stephen Hahn is correctly identified as a former FDA commissioner; Brett Giroir's characterization as "briefly acting commissioner" is accurate. No outright factual errors are evident, but several specific claims rest on unverified or second-hand sourcing.

Framing — Mixed

1. "soap opera whose cliffhangers leave entire industries in suspense" — The opening characterization is authorial voice, not attributed analysis. It preloads the piece with a drama framing that colors subsequent neutral reporting.
2. "organizational disarray, surprise policy moves and political interference" — Listed without attribution in the "Why it matters" block. These are interpretive characterizations dressed as contextual fact; "political interference" in particular is a loaded construction.
3. "appeared to have been spared" — The hedged passive construction is appropriately cautious given uncertainty, a fair editorial choice.
4. "more mainstream figure" — Used twice without attribution or definition. "Mainstream" implies Makary is outside the mainstream — an editorial judgment presented as industry expectation.
5. "less disruptive, pro-industry commissioner" — This framing is attributed to Capstone analyst Will Humphrey, so it is properly sourced; the piece could have noted Humphrey's firm advises investors, which would contextualize his framing.

Source balance

Ratio: Two Wall Street analysts, one anonymous official, one presidential non-answer. Zero voices from FDA staff, public-health advocates, patient groups, or Makary himself. No congressional voices, despite a Senate hearing mentioned. The piece's effective perspective is the investor/industry lens, with no countervailing public-health or consumer-safety voice.

Omissions

1. What triggered the firing reports? The article does not say who first reported Makary's imminent firing or what prompted it — a significant gap given that the entire news hook rests on those reports.
2. Makary's own response. He is described as "appearing to have been spared" but is never quoted or noted as declining comment. A sitting commissioner's silence (or unavailability) is relevant.
3. Historical precedent for mid-term FDA commissioner ousters. Readers have no sense of how unusual or routine this kind of leadership turbulence is; prior administrations' FDA commissioner tenures would provide useful baseline.
4. HHS Secretary's role. A "White House official told Politico that senior HHS leaders were pushing for the possible firing" — but HHS Secretary Robert F. Kennedy Jr. is not named or discussed, omitting the most likely relevant figure.
5. Specifics of Makary's contested decisions. "Drama around abortion pills, flavored vapes, vaccine issues and drugs for rare diseases" lists controversies without any detail, leaving readers unable to assess the basis for dissatisfaction or support.

What it does well

• The piece openly acknowledges its own uncertainty: "All of the reports were hedged with the now-standard reminder that Trump often changes his mind" — a transparent caveat that models appropriate epistemic humility for a breaking story.
• The staffing data point — "biologics and drug evaluation centers each down more than 19% since Trump took office" — is concrete and gives readers a measurable stake in the outcome beyond political drama.
• "There are also real questions about whether the future FDA leadership will agree with positions this FDA leadership has taken but not yet put into formal guidance" (Meekins) usefully flags a regulatory continuity issue that readers in affected industries would want to track.
• The piece avoids overconfident declarative claims about Makary's fate, consistently using conditional language ("if Makary does leave," "apparent survival").

Rating

Overall: 6/10 — A competent breaking-news brief hampered by thin sourcing, an industry-skewed perspective, and authorial framing that outpaces the evidence.